Page 5,106«..1020..5,1055,1065,1075,108..5,1205,130..»

NANOBIOTIX Announces the Selection of Its Second NanoXray Product, NBTX-IV and a Collaboration With the National …

Posted: Published on June 26th, 2013

PARIS--(Marketwired - Jun 26, 2013) - NANOBIOTIX (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. It is the second product of the NanoXray pipeline which is designed for systemic administration (intravenous injection). This product has been selected by the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization on the basis of its potential to impact cancer treatment. NBTX-IV is based on Nanobiotix's proprietary NanoXray platform. It is designed to be administered intravenously to target deep-seated tumors and lymph nodes which may have been invaded locally by cancer cells. The product aims to enhance radiotherapy energy to destroy cancer cells and reduce the subsequent escape of malignant cells localized in neighboring tissues cells or lymph nodes. Target indications include lung carcinoma, pancreatic cancer or brain metastases. As part of the collaboration with NCI, the NCL will perform pre-clinical characterization of NBTX-IV that will support Nanobiotix's filing of an Investigational New Drug (IND) with the FDA. In parallel, Nanobiotix will conduct additional preclinical testing to provide a complete dossier for submission. The NCL was established to investigate the use of nanoparticulate material … Continue reading →

Comments Off on NANOBIOTIX Announces the Selection of Its Second NanoXray Product, NBTX-IV and a Collaboration With the National …

Karmanos Cancer Center Blood and Marrow Stem Cell Transplant Program Gets Foundadtion Accreditation

Posted: Published on June 25th, 2013

(PRNewsFoto/Karmanos Cancer Institute) DETROIT The Barbara Ann Karmanos Cancer Centers Blood and Marrow Stem Cell Transplant Program has received full accreditation from the Foundation for the Accreditation of Cellular Therapy, the highest level and the most extensive spectrum of accreditation offered by FACT for Bone Marrow Transplant Programs. This includes accreditation for both adult and pediatric clinical programs, apheresis collection, marrow harvest collection and stem cell processing. The accreditation is effective for three years beginning Sept. 30, 2012. Additionally, Karmanos BMT program, the largest of its kind in Michigan, was honored with an award for being a site that has maintained continuous FACT accreditation for 10 years or more. Karmanos first FACT accreditation was received in 2000. We are extremely pleased about receiving full accreditation from FACT, said Toni Henderson-Clark, MSN, MSBA, RN, CCRN, quality and regulatory specialist for the Blood and Marrow Stem Cell Transplant Program at Karmanos. We make it an absolute priority to provide the best and most effective therapies for those patients who come to us for bone marrow transplants. The fact that we have maintained FACT accreditation for so long speaks to that commitment. Karmanos doctors performed 273 bone marrow transplants in 2012 and expect … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Karmanos Cancer Center Blood and Marrow Stem Cell Transplant Program Gets Foundadtion Accreditation

Study sets guidelines for stem cell transplants in older patients with myelodysplastic syndromes

Posted: Published on June 25th, 2013

June 24, 2013 A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes (MDS) -- the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia. Using mathematical models to analyze hundreds of MDS cases from around the world, the researchers found reduced intensity transplants of donor stem cells are advisable for patients aged 60-70 who have higher-risk forms of MDS that are likely to turn into leukemia in the near future. For patients with lower-risk MDS, non-transplant treatments are preferable, the model indicates. The research was reported online today in the Journal of Clinical Oncology. "Our study helps inform older MDS patients and their doctors whether a stem cell transplant is preferred or whether it makes more sense to pursue other options," says John Koreth, MBBS, DPhil, medical oncologist in the Division of Hematologic Malignancies at Dana-Farber, who is the study's lead author and co-principal investigator (with Joseph Pidala, MD, MS, of the H. Lee Moffitt Cancer & Research Institute, and senior author Corey Cutler, MD, MPH, of the … Continue reading →

Posted in Stem Cell Transplant | Comments Off on Study sets guidelines for stem cell transplants in older patients with myelodysplastic syndromes

Was Stem Cell therapy behind death of 3 Solons?

Posted: Published on June 25th, 2013

Manila, Philippines --- Several congressmen have indeed undergone stem cell therapy in Germany and two of them died while serving the 15th Congress. This was gathered from several sources as one outgoing congressman disclosed that a group of Mindanao mayors are set to depart for Europe to visit stem cell clinics in Germany. ''But virility and aesthetic enhancements are the reasons for the trip,'' said outgoing Agham Party-list Rep. Angelo Palmones in an interview yesterday. Palmones admitted that one of the veteran solons who died during the 15th Congress was a stem cell therapy patient but whether or not the procedure contributed to his death remains unknown. ''He died of heart attack but the purpose of his stem cell treatment was to improve virility,'' said Palmones, outgoing vice chairman of the House Committee on Science and Technology. Two others reportedly flew to Europe to seek treatment for cancer but both died. A former broadcaster, Palmones authored House Resolution No. 1075 calling for a congressional investigation in aid of legislation on the operation of stem cell therapy clinics in malls in a bid to ensure the ''safety and security of patients.'' In a press statement the other day, the Philippine Medical … Continue reading →

Comments Off on Was Stem Cell therapy behind death of 3 Solons?

FDA approves Astellas’ Mycamine for injection

Posted: Published on June 25th, 2013

Article updated: 6/24/2013 1:23 PM The U.S. Food and Drug Administration as approved a supplemental new drug application for the use of Northbrook-based Astellas Pharma U.S. drug Mycamine for injection by intravenous infusion for the treatment of pediatric patients four months and older with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplants. "We are pleased with FDA's approval of Mycamine for use in pediatric patients four months and older," said Sef Kurstjens, M.D., chief medical officer, Astellas Pharma, Inc. "This expanded indication supports the safety and efficacy of Mycamine and delivers on our mission to provide treatments that can help to improve patient care." Candida, a yeast that causes common fungal infections, is the third most common cause of pediatric health care associated bloodstream infection. Mycamine inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida, the company said in a release. The overall safety of Mycamine was assessed in 479 patients, ages three days through 16 years, who received at least one dose of Mycamine in 11 separate clinical trials. Continue reading here: FDA approves Astellas’ Mycamine for injection … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on FDA approves Astellas’ Mycamine for injection

FDA Approves Pediatric Indication for Astellas' MYCAMINE® (micafungin sodium) for Injection

Posted: Published on June 25th, 2013

NORTHBROOK, Ill., June 24, 2013 /PRNewswire/ --Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), announced that the U.S. Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA) for the use of MYCAMINE (micafungin sodium) for injection by intravenous infusion for the treatment of pediatric patients four months and older with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplants (HSCT). "We are pleased with FDA's approval of MYCAMINE for use in pediatric patients four months and older," said Sef Kurstjens, M.D., chief medical officer, Astellas Pharma, Inc. "This expanded indication supports the safety and efficacy of MYCAMINE and delivers on our mission to provide treatments that can help to improve patient care." "Candida infections are a significant concern to pediatric healthcare professionals, and there are limited treatment options," said Antonio C. Arrieta, M.D., Director Pediatric Infectious Diseases, Children's Hospital of Orange County and Clinical Professor, Pediatrics, University of California, Irvine. "Because MYCAMINE has been shown to be safe and effective in treating candidemia in many adult patients, it is an important new option for treating Candida infections … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on FDA Approves Pediatric Indication for Astellas' MYCAMINE® (micafungin sodium) for Injection

Americord Applauds Study on Stem Cell Therapy for Congenital Heart Defects

Posted: Published on June 25th, 2013

NEW YORK, June 24, 2013 /PRNewswire/ --Americord today applauded a new study being conducted by Mayo Clinic to determine whether children with hypoplastic left heart syndrome (HLHS) can be successfully treated with stem cells from their own umbilical cord blood. HLHS is a congenital heart defect where infants are born with a severely underdeveloped left ventricle essentially half a heart. Mayo Clinic is a non-profit worldwide leader in medical care, research and education that spends over $500 million a year on research and employs nearly 3,800 physicians and scientists. In the United States, about 1,000 babies are born each year with HLHS. Babies with HLHS have heart valves that are either too small to allow sufficient blood flow, or valves that are closed altogether. In the study being done by Mayo Clinic, umbilical cord blood stem cells will be collected from infants born with HLHS, and they will be preserved. Approximately four to six months later, the stem cells will be injected directly into the infant's heart muscle. Since stem cells are able to develop into many different kinds of cell types found in the human body, researchers are hopeful that this treatment will increase the strength and volume of … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Americord Applauds Study on Stem Cell Therapy for Congenital Heart Defects

Dr Jemima Whyte Stem Cells for Species Conservation – Video

Posted: Published on June 25th, 2013

Dr Jemima Whyte Stem Cells for Species Conservation Jemima Whyte is a Postdoctoral Research Associate in Stem Cell Biology at The Roslin Institute, University of Edinburgh. She obtained her Wellcome Trust PhD ... By: Jemima Whyte … Continue reading →

Comments Off on Dr Jemima Whyte Stem Cells for Species Conservation – Video

Stem Cell Treatment for Diabetes in India – Video

Posted: Published on June 25th, 2013

Stem Cell Treatment for Diabetes in India Major effects of diabetes mellitus treatment with stem cells are listed below. 1. Decrease of glycemia in patients with new-onset insulin-dependent diabetes ... By: StemRx BioScience … Continue reading →

Comments Off on Stem Cell Treatment for Diabetes in India – Video

Early complications of knee replacement surgery… a need for stem cell treatment instead? – Video

Posted: Published on June 25th, 2013

Early complications of knee replacement surgery... a need for stem cell treatment instead? http://www.stemcellsarthritistreatment.com Active Baby Boomers with knee arthritis are getting knee replacements at an all time high. While knee replacement ... By: Nathan Wei … Continue reading →

Comments Off on Early complications of knee replacement surgery… a need for stem cell treatment instead? – Video

Page 5,106«..1020..5,1055,1065,1075,108..5,1205,130..»